GlassScriptPhysician profile
Alan O Khadavi
NPI 1841220621
$17,435.27
in general payments reported to CMS, 2019-2025
47 companies · $3,136 in 2025
The $3,136 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $886 · 2021: $1,555 · 2022: $3,361 · 2023: $3,800 · 2024: $3,467 · 2025: $3,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,386.74 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $3,209.07 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $2,220.99 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,869.27 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $1,550.76 | 2019-2025 | |
| Genzyme Corporation | $1,509.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,137.42 | 2019-2025 | |
| Amgen INC. | $1,021.43 | 2021-2025 | Tezspire, Prolia, Evenity |
| Abbvie INC. | $688.10 | 2022-2025 | |
| Genentech USA, INC. | $525.41 | 2020-2025 | Xolair |
| Optinose US, INC. | $481.07 | 2019-2025 | |
| Incyte Corporation | $363.17 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $340.61 | 2019-2025 | Adbry |
| Hikma Pharmaceuticals USA | $272.15 | 2022-2025 | Ryaltris |
| Octapharma USA, INC. | $231.02 | 2019-2024 | Cutaquig, Panzyga |
| Organon LLC | $170.14 | 2025 | Vtama |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Khadavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.